Page number 11
6 07 June 2021 Semaglutide 2.4 mg approval in the US In STEP 5, semaglutide 2.4 mg sh over 2 years Clinically relevant and sustained weight loss in patients with obesity or overweight % change in body weight Change in body weight in % depicts observed means since time of randomisation; trial product estimand.
Page number 12
howed sustained weight loss Novo Nordisk ® Data from STEP 5 17% weight loss after 104 weeks 40% of patients lost ≥ 20% of their body weight after 104 weeks Semaglutide appeared to have a safe and well-tolerated profile Improvements in lipid profiles as well as C-reactive protein
